Rimidi, a cloud-based software platform that enables personalized management of chronic cardiometabolic conditions across populations, today announced a new disease ‘view’ within its platform – obesity. Obesity becomes the fifth disease state being managed within the software, along with type 2 diabetes, heart failure, nonalcoholic fatty liver disease and cardiovascular disease. Rimidi’s platform works within the electronic health record (EHR) to preemptively identify and manage cardiometabolic diseases by combining data from multiple sources into disease ‘views’ that provide a holistic overview of a patient.
The addition of obesity to Rimidi’s platform addresses the evolving policies and care around obesity, as the chronic disease requires increased medical attention. Today, obesity affects nearly 40% of Americans and remains one of the biggest contributors to preventable chronic disease and rising US healthcare costs. In fact, this global epidemic is associated with an increased risk of disease and mortality, and costs anywhere from $147 billion to nearly $210 billion to manage per year.
“Obesity is a global epidemic in both children and adults, and it’s associated with numerous comorbidities, which manifest differently in each individual patient,” said Lucienne Ide, M.D., Ph.D., founder of Rimidi. “With new innovations in healthcare, however, clinicians are better equipped to combat the obesity epidemic head-on. That’s where Rimidi comes into play. By adding this condition into our existing platform, we can empower physicians with the tools and technology they need to better identify patients who may be at risk.”
The Rimidi platform works within the electronic health record (EHR) to support better management of cardiometabolic conditions through distinct disease views. With the addition of the new obesity view, clinicians can better manage patients based off the latest evidence and guidelines, as well as offer virtual care support, such as remote monitoring and digital health education. In addition to consolidating pertinent information from the EHR that impacts clinical decision making, the new view performs the following:
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Alerts clinicians to risk factors associated with obesity – including hypertension, type 2 diabetes, sleep apnea, PCOS, depression, thyroid disease and nonalcoholic fatty liver disease – and flags whether standard of care for screening and risk-reduction are being met.
Displays patient’s atherosclerotic-cardiovascular-disease (ASCVD) risk scores so clinicians can easily see patient’s 10-year risk for heart disease or stroke.
Identifies gaps in prescribing standards, including anti-diabetic and anti-obesity medications, lipid lowering agents, ACE inhibitors, ARBs and aspirin.
“As health systems move to value-based contracting, accurately documenting chronic conditions – such as obesity – is not only important for patient care, but also for risk-adjustment payment models,” said Josh Claman, CEO of Rimidi. “With Rimidi, clinical teams will now be prompted when diagnostic codes and biometrics, such as BMI, are discordant, allowing physicians to address Hierarchical Condition Category coding opportunities at the point of care.”
Obesity is now broadly recognized as a chronic disease. Rimidi is aligned with supporting clinicians, patients and payer in recognizing this disease, optimizing its medical management, reducing cardiovascular risk and supporting self-management efforts.
Source: PR Web
